# Immunovant, Inc. (IMVT) stock: price and valuation

URL: https://funkfolio.com/stock/IMVT

> Immunovant, Inc. (IMVT) trades at $33.23 and is worth $6.88B. Valuation against its own history and up to 20 years of financials.

---

## Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT) is a healthcare company (biotechnology) based in the United States. The share price is $33.23, down 0.15% on the day, which values the company at $6.88B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $33.23 −0.15% today
- **Market value:** $6.88B
- **200-week average:** $26.21 27% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 17:23 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Immunovant, Inc. in more detail

IMVT trades at -11.8× next year's expected earnings. It sits 27% above its 200-week average of $26.21.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

3 of the superinvestors tracked here hold IMVT, including Andrew Spokes (1.1% of the portfolio), Julian and Felix Baker (1.0% of the portfolio), David Einhorn (0.1% of the portfolio).

### Superinvestors holding IMVT

3 of the investors tracked here report a position in their latest 13F filing.

- [Andrew Spokes Farallon Capital Management](https://funkfolio.com/gurus/farallon) 1.14% of portfolio · $218.6M · added · Q3 2026
- [Julian and Felix Baker Baker Bros. Advisors](https://funkfolio.com/gurus/baker-brothers) 1.05% of portfolio · $209.4M · trimmed · Q2 2026
- [David Einhorn Greenlight Capital](https://funkfolio.com/gurus/david-einhorn) 0.09% of portfolio · $3.6M · Q2 2026

### Health Care companies of similar size

- [Kiniksa Pharmaceuticals International KNSA](https://funkfolio.com/stock/KNSA)
- [ImmunityBio IBRX](https://funkfolio.com/stock/IBRX)
- [Cytokinetics CYTK](https://funkfolio.com/stock/CYTK)
- [ABIVAX ABVX](https://funkfolio.com/stock/ABVX)
- [Bausch + Lomb BLCO](https://funkfolio.com/stock/BLCO)
- [Amneal Pharmaceuticals AMRX](https://funkfolio.com/stock/AMRX)
- [Caris Life Sciences CAI](https://funkfolio.com/stock/CAI)
- [Axsome Therapeutics AXSM](https://funkfolio.com/stock/AXSM)
- [Chemed CHE](https://funkfolio.com/stock/CHE)
- [Oruka Therapeutics ORKA](https://funkfolio.com/stock/ORKA)
- [Arrowhead Pharmaceuticals ARWR](https://funkfolio.com/stock/ARWR)
- [MSA Safety MSA](https://funkfolio.com/stock/MSA)

Side by side: [IMVT vs CAI (Immunovant, Inc. vs Caris Life Sciences)](https://funkfolio.com/compare/cai-vs-imvt) [IMVT vs AMRX (Immunovant, Inc. vs Amneal Pharmaceuticals)](https://funkfolio.com/compare/amrx-vs-imvt) [IMVT vs BLCO (Immunovant, Inc. vs Bausch + Lomb)](https://funkfolio.com/compare/blco-vs-imvt) [IMVT vs AXSM (Immunovant, Inc. vs Axsome Therapeutics)](https://funkfolio.com/compare/axsm-vs-imvt) [IMVT vs CHE (Immunovant, Inc. vs Chemed)](https://funkfolio.com/compare/che-vs-imvt)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Immunovant, Inc. (IMVT): questions and answers

**What is Immunovant, Inc.'s market cap?**

Immunovant, Inc. is valued at $6.88B at a share price of $33.23.

**Is IMVT above its 200-week moving average?**

Yes. IMVT is 26.8% above its 200-week average of $26.21. Long-term investors watch that line because strong companies rarely trade below it for long.

**Does IMVT pay a dividend?**

Immunovant, Inc. does not currently pay a regular dividend.

**Which famous investors own IMVT?**

In their latest quarterly filings, Andrew Spokes (1.1% of the portfolio), Julian and Felix Baker (1.0% of the portfolio), David Einhorn (0.1% of the portfolio) hold IMVT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

**When does Immunovant, Inc. report earnings next?**

Immunovant, Inc.'s next earnings report is expected on February 5, 2027. The date comes from the market data feed and companies do move it.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Immunovant, Inc. (IMVT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT

Underlying data: Yahoo Finance; company filings with the SEC.
